Dementia and Value of Home Time

痴呆症和家庭时间的价值

基本信息

  • 批准号:
    10208263
  • 负责人:
  • 金额:
    $ 224.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-30 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

There is a paucity of quality of life (QoL) measures for persons living with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) (hereafter called PWD). Without them, we cannot assess the effectiveness of interventions, policies, or health system investments that aim to improve QoL for PWD. Such measures must acknowledge a person’s preferences and well-being, as well as dynamic changes such as where they live and receive care day-to-day. Staying in one’s home remains the dominant preference among PWD. Therefore, if more home time reflects higher quality of life, ‘home time’ outcome measures are firmly person-centered and could assess population health using ubiquitous claims data. No consensus exists, however, on what health care settings to include in a home time measure. A key reason for our incomplete understanding is that we lack the perspectives of key stakeholders–PWD and their family and friends who help them (caregivers). Nor do we know which definitions of home time most closely relate to person-centered outcomes (PCOs) that matter to PWD. The overarching goal is to arrive at a home time measure that most closely reflects quality of life for PWD and to identify intervenable risk factors that could increase QoL by increasing home time. Importantly, distinct preferences will likely merit a caregiver-version that most closely reflects their QoL. In Aim 1, we will engage a stakeholder panel and then hold in-depth interviews to identify how quality of life for PWD and for their caregivers varies depending on the PWD’s time spent in different health care settings (e.g. emergency department, outpatient surgery, inpatient, nursing home, and assisted living). In Aim 2, we will use mixed methods to develop a single home time measure for PWD that is most closely reflective of PCOs known to matter to PWD (and a separate measure for caregivers). We will link survey data with Medicare and Medicaid claims to allow a more thorough examination of candidate settings than has ever occurred. We will integrate Aim 1 data and validation results from quantitative analyses in order to finalize a home time measure for PWD and one for caregivers. In Aim 3, we will explore how intervenable risk factors that contribute to low QoL for PWD and their caregivers relate to the newly developed home time measures. Because we do not yet understand the relative importance of home, clinical, and social risk factors or how they operate together to jointly influence home time, we will use machine learning to identify impactful risk factors. Advancing the science of home time measurement is urgent, not only for Persons living with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) and caregivers, but also for health systems, given that CMS has launched demonstration programs proposing use of a home time measure as a performance metric for payment policy design. A Policy Convening meeting will help us disseminate best practices for use of the home time measure(s) and minimize negative unintended consequences of any nationally disseminated performance measure. In addition, identifying intervenable risk factors that could be addressed to increase home time for PWD will inform future interventions and practice changes.
对于患有阿尔茨海默病和阿尔茨海默病相关痴呆(AD/ADRD)(以下称为PWD)的人,缺乏生活质量(QoL)测量。如果没有他们,我们就无法评估旨在改善残疾人生活质量的干预措施、政策或卫生系统投资的有效性。这些措施必须承认一个人的偏好和福祉,以及动态变化,如他们的生活和日常护理地点。留在家中仍然是残疾人的主要偏好。因此,如果更多的在家时间反映了更高的生活质量,“在家时间”的结果措施是坚定的人为中心,可以评估人口健康使用无处不在的索赔数据。然而,在家庭时间措施中应包括哪些卫生保健环境方面,还没有达成共识。我们不完全理解的一个关键原因是,我们缺乏关键残疾人的观点-残疾人及其帮助他们的家人和朋友(照顾者)。我们也不知道哪些家庭时间的定义与以人为本的结果(PCO)最密切相关,这对PWD很重要。总体目标是达到一个家庭时间的措施,最密切地反映了生活质量的PWD和识别可干预的风险因素,可以增加生活质量的增加家庭时间。重要的是,不同的偏好可能值得一个最能反映他们生活质量的转换版本。在目标1中,我们将与利益相关者小组合作,然后进行深入访谈,以确定PWD及其护理人员的生活质量如何根据PWD在不同医疗保健环境(例如急诊室,门诊手术,住院,疗养院和辅助生活)中花费的时间而变化。在目标2中,我们将使用混合方法为PWD开发一个最能反映已知对PWD重要的PCO的单一在家时间指标(以及针对护理人员的单独指标)。我们将把调查数据与医疗保险和医疗补助索赔联系起来,以便对候选人的设置进行比以往任何时候都更彻底的检查。我们将整合目标1数据和定量分析的验证结果,以最终确定PWD和护理人员的家庭时间测量。在目标3中,我们将探讨导致PWD及其护理人员生活质量低下的可干预风险因素与新开发的在家时间测量方法之间的关系。由于我们还不了解家庭、临床和社会风险因素的相对重要性,也不知道它们如何共同影响家庭时间,因此我们将使用机器学习来识别有影响力的风险因素。推进家庭时间测量的科学是紧迫的,不仅对阿尔茨海默病和阿尔茨海默病相关痴呆症(AD/ADRD)和照顾者,而且对卫生系统,鉴于CMS已经启动了示范计划,建议使用家庭时间测量作为支付政策设计的绩效指标。政策召集会议将帮助我们传播使用在家时间衡量标准的最佳做法,并尽量减少任何全国传播的业绩衡量标准的负面意外后果。此外,确定可干预的风险因素,可以解决,以增加残疾人的家庭时间将告知未来的干预措施和实践的变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Courtney Harold Van Houtven其他文献

Long-term care insurance within married couples: Can’t insure one without the other?
  • DOI:
    10.1007/s11150-025-09779-0
  • 发表时间:
    2025-05-23
  • 期刊:
  • 影响因子:
    2.200
  • 作者:
    Norma B. Coe;R. Tamara Konetzka;Chuxuan Sun;Courtney Harold Van Houtven
  • 通讯作者:
    Courtney Harold Van Houtven

Courtney Harold Van Houtven的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Courtney Harold Van Houtven', 18)}}的其他基金

HSR&D Merit Review Research Career Scientist Award
高铁
  • 批准号:
    10250600
  • 财政年份:
    2021
  • 资助金额:
    $ 224.67万
  • 项目类别:
HSR&D Merit Review Research Career Scientist Award
高铁
  • 批准号:
    10489338
  • 财政年份:
    2021
  • 资助金额:
    $ 224.67万
  • 项目类别:
VA Caregiver Support Evaluation Center (VA-CARES Evaluation Center)
VA 看护者支持评估中心(VA-CARES 评估中心)
  • 批准号:
    9075408
  • 财政年份:
    2014
  • 资助金额:
    $ 224.67万
  • 项目类别:
Helping Invested Families Improve Veterans Experiences Study (HI-FIVES)
帮助投资家庭改善退伍军人体验研究 (HI-FIVES)
  • 批准号:
    8479932
  • 财政年份:
    2013
  • 资助金额:
    $ 224.67万
  • 项目类别:
Family Structure, Informal Care and Long-term Care Insurance
家庭结构、非正式护理和长期护理保险
  • 批准号:
    8517487
  • 财政年份:
    2011
  • 资助金额:
    $ 224.67万
  • 项目类别:
Family Structure, Informal Care and Long-term Care Insurance
家庭结构、非正式护理和长期护理保险
  • 批准号:
    8339357
  • 财政年份:
    2011
  • 资助金额:
    $ 224.67万
  • 项目类别:
Family Structure, Informal Care and Long-term Care Insurance
家庭结构、非正式护理和长期护理保险
  • 批准号:
    8212741
  • 财政年份:
    2011
  • 资助金额:
    $ 224.67万
  • 项目类别:
Informal Care of Older Adults and Medicare Expenditures
老年人的非正式护理和医疗保险支出
  • 批准号:
    6557350
  • 财政年份:
    2002
  • 资助金额:
    $ 224.67万
  • 项目类别:
Informal Care of Older Adults and Medicare Expenditures
老年人的非正式护理和医疗保险支出
  • 批准号:
    6660726
  • 财政年份:
    2002
  • 资助金额:
    $ 224.67万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 224.67万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了